Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Aakash Desai, Justin F Gainor, Aparna Hegde, Alison M Schram, Giuseppe Curigliano, Sumanta Pal, Stephen V Liu, Balazs Halmos, Roman Groisberg, Enrique Grande, Tomislav Dragovich, Marc Matrana, Neeraj Agarwal, Sant Chawla, Shumei Kato, Gilberto Morgan, Pashtoon M Kasi, Benjamin Solomon, Herbert H Loong, Haeseong Park, Toni K Choueiri, Ishwaria M Subbiah, Naveen Pemmaraju, Vivek Subbiah
Emerging efficacy data have led to the emergency use authorization or approval of COVID-19 vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded patients with active malignancies, and thus data on the safety, tolerability and efficacy of the vaccines in patients with cancer are currently limited. Given the risk posed by the COVID-19 pandemic, decisions regarding the use of vaccines against COVID-19 in patients participating in trials of investigational anticancer therapies need to be addressed promptly...
May 2021: Nature Reviews. Clinical Oncology
#2
JOURNAL ARTICLE
Catherine M Brown, Johanna Vostok, Hillary Johnson, Meagan Burns, Radhika Gharpure, Samira Sami, Rebecca T Sabo, Noemi Hall, Anne Foreman, Petra L Schubert, Glen R Gallagher, Timelia Fink, Lawrence C Madoff, Stacey B Gabriel, Bronwyn MacInnis, Daniel J Park, Katherine J Siddle, Vaira Harik, Deirdre Arvidson, Taylor Brock-Fisher, Molly Dunn, Amanda Kearns, A Scott Laney
During July 2021, 469 cases of COVID-19 associated with multiple summer events and large public gatherings in a town in Barnstable County, Massachusetts, were identified among Massachusetts residents; vaccination coverage among eligible Massachusetts residents was 69%. Approximately three quarters (346; 74%) of cases occurred in fully vaccinated persons (those who had completed a 2-dose course of mRNA vaccine [Pfizer-BioNTech or Moderna] or had received a single dose of Janssen [Johnson & Johnson] vaccine ≥14 days before exposure)...
August 6, 2021: MMWR. Morbidity and Mortality Weekly Report
#3
JOURNAL ARTICLE
Jamie Lopez Bernal, Nick Andrews, Charlotte Gower, Eileen Gallagher, Ruth Simmons, Simon Thelwall, Julia Stowe, Elise Tessier, Natalie Groves, Gavin Dabrera, Richard Myers, Colin N J Campbell, Gayatri Amirthalingam, Matt Edmunds, Maria Zambon, Kevin E Brown, Susan Hopkins, Meera Chand, Mary Ramsay
BACKGROUND: The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the globe, including a notable increase in cases in the United Kingdom. The effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines against this variant has been unclear. METHODS: We used a test-negative case-control design to estimate the effectiveness of vaccination against symptomatic disease caused by the delta variant or the predominant strain (B...
July 21, 2021: New England Journal of Medicine
#4
JOURNAL ARTICLE
Gowthami M Arepally, Thomas L Ortel
Development of vaccines to fight COVID19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti-platelet factor 4 antibodies. In this Spotlight article, we will discuss the recently described complication of vaccine-induced immune thrombotic thrombocytopenia (VITT) occurring in response to certain COVID19 vaccines. Although information about this clinical condition is rapidly evolving, we will summarize our current understanding of VITT...
June 1, 2021: Blood
#5
JOURNAL ARTICLE
Merryn Voysey, Sue Ann Costa Clemens, Shabir A Madhi, Lily Y Weckx, Pedro M Folegatti, Parvinder K Aley, Brian Angus, Vicky L Baillie, Shaun L Barnabas, Qasim E Bhorat, Sagida Bibi, Carmen Briner, Paola Cicconi, Elizabeth A Clutterbuck, Andrea M Collins, Clare L Cutland, Thomas C Darton, Keertan Dheda, Christina Dold, Christopher J A Duncan, Katherine R W Emary, Katie J Ewer, Amy Flaxman, Lee Fairlie, Saul N Faust, Shuo Feng, Daniela M Ferreira, Adam Finn, Eva Galiza, Anna L Goodman, Catherine M Green, Christopher A Green, Melanie Greenland, Catherine Hill, Helen C Hill, Ian Hirsch, Alane Izu, Daniel Jenkin, Carina C D Joe, Simon Kerridge, Anthonet Koen, Gaurav Kwatra, Rajeka Lazarus, Vincenzo Libri, Patrick J Lillie, Natalie G Marchevsky, Richard P Marshall, Ana V A Mendes, Eveline P Milan, Angela M Minassian, Alastair McGregor, Yama F Mujadidi, Anusha Nana, Sherman D Padayachee, Daniel J Phillips, Ana Pittella, Emma Plested, Katrina M Pollock, Maheshi N Ramasamy, Adam J Ritchie, Hannah Robinson, Alexandre V Schwarzbold, Andrew Smith, Rinn Song, Matthew D Snape, Eduardo Sprinz, Rebecca K Sutherland, Emma C Thomson, M Estée Török, Mark Toshner, David P J Turner, Johan Vekemans, Tonya L Villafana, Thomas White, Christopher J Williams, Alexander D Douglas, Adrian V S Hill, Teresa Lambe, Sarah C Gilbert, Andrew J Pollard
BACKGROUND: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks. The planned roll-out in the UK will involve vaccinating people in high-risk categories with their first dose immediately, and delivering the second dose 12 weeks later. Here, we provide both a further prespecified pooled analysis of trials of ChAdOx1 nCoV-19 and exploratory analyses of the impact on immunogenicity and efficacy of extending the interval between priming and booster doses...
March 6, 2021: Lancet
#6
JOURNAL ARTICLE
Tamara Pilishvili, Katherine E Fleming-Dutra, Jennifer L Farrar, Ryan Gierke, Nicholas M Mohr, David A Talan, Anusha Krishnadasan, Karisa K Harland, Howard A Smithline, Peter C Hou, Lilly C Lee, Stephen C Lim, Gregory J Moran, Elizabeth Krebs, Mark Steele, David G Beiser, Brett Faine, John P Haran, Utsav Nandi, Walter A Schrading, Brian Chinnock, Daniel J Henning, Frank LoVecchio, Joelle Nadle, Devra Barter, Monica Brackney, Amber Britton, Kaytlynn Marceaux-Galli, Sarah Lim, Erin C Phipps, Ghinwa Dumyati, Rebecca Pierce, Tiffanie M Markus, Deverick J Anderson, Amanda K Debes, Michael Lin, Jeanmarie Mayer, Hilary M Babcock, Nasia Safdar, Marc Fischer, Rosalyn Singleton, Nora Chea, Shelley S Magill, Jennifer Verani, Stephanie Schrag
Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting...
May 21, 2021: MMWR. Morbidity and Mortality Weekly Report
#7
RANDOMIZED CONTROLLED TRIAL
Robert W Frenck, Nicola P Klein, Nicholas Kitchin, Alejandra Gurtman, Judith Absalon, Stephen Lockhart, John L Perez, Emmanuel B Walter, Shelly Senders, Ruth Bailey, Kena A Swanson, Hua Ma, Xia Xu, Kenneth Koury, Warren V Kalina, David Cooper, Timothy Jennings, Donald M Brandon, Stephen J Thomas, Özlem Türeci, Dina B Tresnan, Susan Mather, Philip R Dormitzer, Uğur Şahin, Kathrin U Jansen, William C Gruber
BACKGROUND: Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age. Safe, effective vaccines are needed to protect this population, facilitate in-person learning and socialization, and contribute to herd immunity. METHODS: In this ongoing multinational, placebo-controlled, observer-blinded trial, we randomly assigned participants in a 1:1 ratio to receive two injections, 21 days apart, of 30 μg of BNT162b2 or placebo...
July 15, 2021: New England Journal of Medicine
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
